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Abstract
Background: Polypharmacy, often defined as the concomitant use of ≥ 5 medications, has been identified as a
significant global public health threat. Aging and multimorbidity are key drivers of polypharmacy and have been
linked to a broad range of adverse health outcomes and mortality. Patients with chronic kidney disease (CKD) are
particularly at high risk of polypharmacy and use of potentially inappropriate medications given the numerous risk
factors and complications associated with CKD. The aim of this systematic review will be to assess the prevalence of
polypharmacy among adult patients with CKD, and the potential association between polypharmacy and adverse
health outcomes within this population.
Methods/design: We will search empirical databases such as MEDLINE, Embase, Cochrane Library, CINAHL, Web of
Science, and PsycINFO and grey literature from inception onwards (with no language restrictions) for observational
studies (e.g., cross-sectional or cohort studies) reporting the prevalence of polypharmacy in adult patients with CKD
(all stages including dialysis). Two reviewers will independently screen all citations, full-text articles, and extract data.
Potential conflicts will be resolved through discussion. The study methodological quality will be appraised using an
appropriate tool. The primary outcome will be the prevalence of polypharmacy. Secondary outcomes will include
any adverse health outcomes (e.g., worsening kidney function) in association with polypharmacy. If appropriate, we
will conduct random effects meta-analysis of observational data to summarize the pooled prevalence of
polypharmacy and the associations between polypharmacy and adverse outcomes. Statistical heterogeneity will be
estimated using Cochran’s Q and I2 index. Additional analyses will be conducted to explore the potential sources of
heterogeneity (e.g., sex, kidney replacement therapy, multimorbidity).
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Discussion: Given that polypharmacy is a major and a growing public health issue, our findings will highlight the
prevalence of polypharmacy, hazards associated with it, and medication thresholds associated with adverse
outcomes in patients with CKD. Our study will also draw attention to the prognostic importance of improving
medication practices as a key priority area to help minimize the use of inappropriate medications in patients with
CKD.
Systematic review registration: PROSPERO registration number: [CRD42020206514].
Keywords: CKD, Polypharmacy, Elderly, Multimorbidity, Adverse effects, Prescriptions
Background
Polypharmacy, the concurrent use of multiple medica-
tions by an individual, is a significant and growing public
health threat worldwide [1–3]. In 2017, the World
Health Organization (WHO) highlighted polypharmacy
as a key action to address unsafe medication practices
and medication errors which are often associated with
significant patient injury and preventable harm [1]. Glo-
bally, the prevalence of polypharmacy continues to in-
crease, with estimates of 10–20% in the general
population and 40–60% in the elderly [4–6]. There is no
standard definition of polypharmacy; various definitions
and related terms have been used (reviewed in detail by
Masnoon et al.) [7]. Variability in the numerical thresh-
old used in characterizing polypharmacy, as well as the
reported inconsistencies regarding duration of therapy,
healthcare setting, and inclusion of over-the-counter
(OTC), and traditional and complementary medicines
often creates challenges when defining polypharmacy
[7]. Most studies, however, define polypharmacy as the
concomitant use of ≥ 5 medications which is supported
by evidence on medication-related adverse effects associ-
ated with polypharmacy [8].
Aging and multimorbidity are the key driving factors
of polypharmacy [2, 3]. It is estimated that about half of
individuals over the age of 65 years have at least three
coexisting chronic conditions, and about 20% have five
or more [ 9]. Given a rising burden of multimorbidity
among the elderly, there is a corresponding increase in
the amount of medication use in this group, thus in-
creasing the prevalence of polypharmacy [2, 3]. In the
USA, more than 4 in 10 older adults take 5 or more pre-
scription medications daily—a marked rise of 300% from
1994 to 2014 [10]. This proportion increases to 7 in 10
older adults if OTC medications and supplements are
counted [11] and nearly 20% of older adults take ≥ 10
drugs [10]. Similarly, the Canadian Institute for Health
Information (CIHI) have reported that almost two-thirds
of individuals aged 65 years and over used ≥ 5 drug clas-
ses, while 27% ≥ 10 and 8.6% used ≥ 15 [12]. Table 1
summarizes other driving forces of polypharmacy.
Polypharmacy is associated with a broad range of ad-
verse health outcomes, resulting in significant costs to
both the patient and the healthcare system [13–15], with
the risk and severity of harm increasing with an increas-
ing number of medications [16]. Polypharmacy has also
Table 1 Drivers of Polypharmacy and Various Associated Negative Consequences
Drivers of Polypharmacy Negative Consequences Associated with
Polypharmacy [13–16]
i. Indiscriminate use of clinical practice guidelines (CPGs) designed for the management of single
diseases in elderly, multimorbid patients [17, 18].
i. Adverse drug events (ADEs)









x. Falls and fractures
xi. Functional decline, disability and frailty
xii. Cognitive impairment and delirium
xiii. Malnutrition
xiv. Decreased quality of life
xv. Nursing home/long-term care placement
xvi. Hospitalizations
xvii. Mortality
ii. Protocol-driven medicine that recommends prescribing medications as the first line of treatment
and “stepping up” drug regimens with higher doses and/or additional drugs if targets are not
reached [17, 19, 20].
iii. Performance standards and incentives that coerce clinicians to follow guidelines focused on
starting medications [18, 19].
iv. Research gaps that leaves many aspects of polypharmacy poorly understood [18, 19].
v. Inadequate clinician training on the management of polypharmacy (including monitoring,
detecting, preventing, and evaluating adverse outcomes associated with polypharmacy) [18, 19].
vi. Fragmented healthcare systems that results in uncoordinated treatment by multiple prescribers
[9, 19, 21].
vii. Growth of the pharmaceutical industry leading to an ever-increasing availability of medications
for a growing number of medical conditions [19].
viii. Influence of the pharmaceutical industry on clinicians [19] and funding of clinical drug trials [22]
and professional societies that publish CPGs [23].
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been strongly associated with adverse drug events
(ADEs), adverse drug reactions (ADRs), drug-drug inter-
actions, and drug-disease interactions [13–15]. In the
USA, ADRs are estimated to claim between 100,000 and
218,000 lives annually and cost the healthcare system up
to $137–177 billion [24]. The true incidence of ADRs
are estimated to be much higher since underreporting is
shown to be as high as 94% [25]. Studies have also
shown that the risk of ADEs increases by up to 7–10%
for each additional medication taken, and that outpa-
tients using 5 or more medications have an 88% in-
creased chance of experiencing an ADE compared to
those taking less medications [26].
Polypharmacy has also been directly associated with
mortality. In a systematic review that investigated the as-
sociation between polypharmacy and mortality, a signifi-
cant association between polypharmacy and death was
observed when polypharmacy was defined as a discrete
variable (pooled-adjusted odds ratio [aOR] 1.08 [95% CI
1.04–1.12]) [27]. When polypharmacy was defined cat-
egorically, a dose-response relationship was also ob-
served across increasing thresholds of medications use,
i.e., 1–4 medications [aOR 1.24]; 5 medications [aOR
1.31] and 6–9 medications [aOR 1.59]. Excessive poly-
pharmacy (i.e., use of ≥ 10 medications) was also signifi-
cantly associated with death [aOR 1.96] [27]. Other
negative consequences associated with polypharmacy are
also summarized in Table 1 [13–23].
An increasingly aging and multimorbid population has
contributed to the rising prevalence of chronic kidney
disease (CKD) [28, 29]. Individuals with CKD are highly
vulnerable to polypharmacy given that CKD risk factors
(e.g., diabetes mellitus and hypertension) and other car-
diovascular diseases and risk factors are more prevalent
in this population [30, 31]. Furthermore, patients with
CKD require additional medications to limit the progres-
sion of CKD and manage disease-related complications
(e.g., anemia, metabolic disorders, hyperlipidemia, min-
eral, and bone disorders) as kidney function deteriorates
[32]. In CKD, all mechanisms of kidney excretion are
impaired, including glomerular filtration, tubular secre-
tion, and reabsorption. Since most drugs are largely
eliminated through the kidneys, reduced kidney function
causes a wide-ranging changes to the pharmacokinetic
(drug absorption, distribution, metabolism, and excre-
tion) and pharmacodynamic (drug-receptor interactions)
properties of drugs thereby increasing the likelihood of
potentially life-threatening toxicities, drug-drug interac-
tions, and ADRs [33, 34]. The substantial burden of
medications in individuals with CKD is well-
documented, with studies showing that between 70.4–
81% of patients with CKD take ≥ 5 medications [35, 36].
In a German study of 5217 patients with CKD, the
prevalence of polypharmacy at baseline and follow-up
was almost 80%, the median number of different medi-
cations per day was 8 (range 0–27), and factors associ-
ated with polypharmacy were increasing CKD stage, age,
body mass index (BMI), diabetes mellitus, cardiovascular
disease, and a history of smoking [35]. Another study
found that 35.5% of older individuals with CKD took ≥
10 medications, vitamins, and supplements [36].
Polypharmacy is also the main reason for potentially
inappropriate medications (PIMs) use, with the number
of PIMs increasing with the number of prescribed medi-
cations [37]. In individuals with CKD, numerous studies
have revealed that PIM use as well as renally inappropri-
ate medications use (RIMs) is common [36–39] and
often overlooked [38, 39]. The prevalence of PIMs is es-
timated to be as much as 62–67% of patients in the in-
patient and ambulatory care setting [40]. The recently
published CKD-REIN study revealed that a large propor-
tion of medications prescribed to patients with CKD
were contraindicated, suggesting a lack of regular and/or
thorough assessment of patients’ medication lists as kid-
ney function declined [41].
The number of older persons is expected to have dou-
bled by 2050 (reaching nearly 2.1 billion) [42], and this
is likely to further increase the burden of multimorbidity
and prevalence of individuals with CKD on polyphar-
macy [28]. Given the relationship between multimorbid-
ity and CKD, and that such patients are at high risk of
polypharmacy, PIMs, and adverse health effects associ-
ated with polypharmacy, this study will provide adequate
information characterizing the burden of these condi-
tions among patients with CKD. This will likely improve
caution when prescribing medications for patients with
CKD and reduce the frequency of adverse health effects
related to polypharmacy in this population.
The aim of this systematic review will be to assess the
prevalence of polypharmacy among adult patients with
CKD, and the potential association between polyphar-
macy and adverse health outcomes within this
population.
Methods/design
The present protocol has been registered within the
PROSPERO database (registration number
CRD42020206514) and is being reported in accordance
with the guidance provided in the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses Proto-
cols (PRISMA-P) statement [43] (see checklist in Add-
itional file 1). The planned review will be reported
according to the Preferred Reporting Items for Reporting
Systematic Reviews and Meta-Analyses (PRISMA) 2020
Statement [44], and the Meta-analysis Of Observational
Studies in Epidemiology (MOOSE) reporting guideline
[45].
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Information sources and search strategies
The following databases will be searched from inception
onwards with no language restriction: MEDLINE,
Embase, Cochrane Library, CINAHL, Web of Science,
and PsycINFO. The search strategy will be developed in
consultation with a research librarian, the study investi-
gators, and with guidance from the Cochrane handbook.
We will also use a combination of controlled vocabulary
search terms (i.e., Medical Subject Headings), and we
will adapt the MEDLINE search strategy for the other
databases. The draft search strategy for MEDLINE is
provided in Additional file 2.
Reference lists of all relevant and selected publications
will be searched manually to identify further studies.
Conference abstracts and grey literature studies will also
be considered from recommended resources in consult-
ation with our medical librarian. As such, we will search
ProQuest Dissertations & Theses Global, and Confer-
ence Proceedings Citation Index (Clarivate Analytics).
Criteria for considering studies for the review
Types of studies
Eligible studies will be observational studies (cohort,
cross-sectional, or health surveys) reporting prevalence
data of polypharmacy. Cross-sectional studies will be the
most appropriate study design to determine the preva-
lence of polypharmacy. Cross-sectional health surveys
are typically used to estimate the point prevalence of
common conditions of long duration.
Types of participants
We will include studies with participants over 18 years
of age, regardless of sex and ethnicity, across the
spectrum of CKD (including those receiving kidney re-
placement therapy), and studies performed in in-patient
and outpatient settings. We will exclude studies where
the prevalence of polypharmacy cannot be computed as
well as review articles, case reports, case studies, images,
and other studies from which relevant data cannot be
obtained even after attempting to contact the authors.
Exposure of interest
We will include studies that explored polypharmacy in
patients with CKD and reported the prevalence of poly-
pharmacy in their study setting with or without report-
ing the duration of therapy and/or healthcare setting
(e.g., ambulatory care, hospitalization). We will define
polypharmacy as the use of ≥ 5 medications (i.e., pre-
scriptions, not pills, or dispensations) and excessive
polypharmacy (hyperpolypharmacy) as use of ≥ 10
medications.
Types of outcome
The primary outcome will be the prevalence of poly-
pharmacy (as described above). Secondary outcomes will
include any adverse health outcomes in association with
polypharmacy. Specifically, we will include studies that
reported an association between polypharmacy and the
following adverse health outcomes: kidney-related out-
comes (such as episodes of acute kidney injury, worsen-
ing of estimated glomerular filtration rate [eGFR],
initiation of dialysis, episodes of hyperkalemia),
cardiovascular-related outcomes (such as fatal and non-
fatal cardiovascular events), all-cause mortality, hospital-
izations, drug-related outcomes (ADRs, ADEs, etc.),
health-related quality of life (HRQoL), and other cogni-
tive and physical decline outcomes.
Data collection and analysis
Study selection
A flow diagram showing details of studies included and
excluded at each stage of the study selection process will
be provided in the final review. We will adopt a 2-stage
collaborative review process for screening and inclusion
of studies. First, 2 investigators (MT and SM) will inde-
pendently review the titles and abstracts of retrieved
studies using the established study inclusion and exclu-
sion criteria. Subsequently, full texts of the selected stud-
ies will be obtained and will be independently assessed
by these reviewers for eligibility. If necessary, any dis-
crepancies will be resolved by a third reviewer (IGO).
For any excluded study, one of the predefined exclusion
criteria will be recorded.
Data extraction and management
Two investigators will independently extract data from
selected studies. The extracted data will be entered into
a standardized form and will be reviewed for accuracy
and completeness. Data elements from the selected stud-
ies will include first author, country, year of publication,
study design, sample size, age, sex, CKD stages, and/or
kidney function (i.e., serum creatinine and/or estimated
glomerular filtration rate), number of comorbidities,
duration of therapy, healthcare setting, mean/median
number of medications, the article’s definition of poly-
pharmacy, prevalence of polypharmacy, and adverse
health outcomes reported. Reported adverse health out-
comes will be grouped into ADRs, ADEs, or others and
recorded as reported from the studies. Authors of the
studies will be contacted for missing or additional data.
If possible, we will calculate missing data using available
information (e.g., imputation). All missing data will be
reported in the data extraction form and risk of bias
table.
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Assessment of risk of bias
Methodological quality of the studies will be evaluated
using the checklist developed by Hoy et al. [46] to assess
the risk of bias from studies. This quality assessment
tool incorporates assessments of risk of bias across core
domains including sampling, the sampling technique
and size, outcome measurement, response rate, and stat-
istical reporting. The overall risk of bias for each study
will be displayed in a risk of bias summary table.
Data synthesis
Study characteristics will be summarized in Tables and
described in texts in the study manuscript.. The decision
to perform a meta-analysis on the primary outcome
(prevalence of polypharmacy) will depend on the assess-
ment of statistical heterogeneity. If heterogeneity be-
tween studies is high (I2 > 50% and deemed to represent
considerable heterogeneity), then data will be reported
descriptively and we will provide a narrative synthesis of
included studies using the Synthesis Without Meta-
analysis (SWiM) reporting guideline as a framework
[47]. If heterogeneity is acceptable, we will pool the
study-specific estimates using a random-effects meta-
analysis model (DerSimonian and Laird) to obtain an
overall summary estimate of the prevalence of polyphar-
macy and rates of the secondary outcomes [48] [49].Het-
erogeneity among studies will be evaluated in relation to
participant characteristics (e.g., comorbidities), number
of medications, and types of adverse health outcomes
(kidney-related/others). We will evaluate heterogeneity
across studies by applying the χ2 test (p < 0.1 will indi-
cate heterogeneity) and quantified using the I2 statistic
(values of < 25%, 25–75%, and > 75% representing low,
medium, and high heterogeneity, respectively) [50]. We
will assess the presence of publication bias using funnel
plots and Egger’s test [51].
Additional analyses
Subgroup analysis will be performed to investigate varia-
tions in prevalence data and potential sources of hetero-
geneity [49]. The following subgroups will be considered
for further analyses: sex (males versus females), age
groups: elderly and very elderly, study setting (in-patient
versus outpatient settings), quality of study (low versus
moderate versus high), patients on kidney replacement
therapy (KRT) versus not receiving KRT, and multimor-
bidity (≤ 3 versus > 3). Significant results will be defined
as p < 0.05.
Confidence in cumulative evidence
The quality of evidence for the primary outcome, i.e.,
prevalence of polypharmacy, will be assessed as “very
low” to “high” in accordance to the Grading of Recom-
mendations Assessment, Development and Evaluation
(GRADE) Workgroup [52]. We will identify limitations
of included studies and suggest improvement where
possible.
Patient and public involvement
Given that this study is a systematic review, there will be
no direct involvement of patients and public.
Ethics and dissemination
Ethical approval will not be required for this study as
data used will be extracted from published studies. Re-
sults of this review will be published using traditional
approaches including open-access peer-reviewed publi-
cations(s), presentations at relevant scientific confer-
ences, reports, and lay summaries.
Discussion
To the best of our knowledge, this review is the first to
comprehensively assess the prevalence of polypharmacy in
patients with CKD as well as reporting the incidence of
adverse health outcomes associated with polypharmacy in
such patients. As polypharmacy is a major and growing
public health issue, our findings will highlight the hazards
associated with polypharmacy as well as medication
thresholds associated with adverse outcomes. Our study
will also draw attention to the prognostic importance of
improving medication practices as a key priority area to
help minimize the use of inappropriate medications in pa-
tients with CKD. A potential limitation of this study could
be non-uniform reporting of adverse outcomes and their
associations with polypharmacy. This could make it diffi-
cult to identify adverse outcomes associated with use of
medications in the CKD population. Another limitation
could be that identified studies are mostly of low quality
which could impact on the final reporting of our out-
comes. Despite these, we expect that the results of this
study will inform medication education, physician practice
guidelines, and various quality improvement initiatives to
address polypharmacy. Any amendments we make to this
protocol when conducting the review will be outlined in
PROSPERO and reported in the final manuscript.
Abbreviations
ADEs: Adverse drug events; ADRs: Adverse drug reactions; BMI: Body mass
index; CIHI: Canadian Institute for Health Information; CKD: Chronic kidney
disease; HRQoL: Health-related quality of life; OTC: Over the counter;
PIMs: Potentially inappropriate medications; PRISMA-P 2015: Preferred
reporting items for systematic reviews and meta-analyses for protocols 2015;
RIMs: Renally inappropriate medications use; WHO: World Health
Organization
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s13643-021-01752-z.
Additional file 1:. PRISMA-P checklist.
Okpechi et al. Systematic Reviews          (2021) 10:198 Page 5 of 7





IGO and MMT drafted the protocol manuscript. IGO and AKB provided
clinical area, systematic review expertise. FY provided methodology
expertise. AKB is the guarantor. All authors read, contributed to, and
approved the final version of the manuscript.
Funding
Funding for this project was received from the Canadian Institute of Health
Research (CIHR) 2019.
Availability of data and materials
The datasets used and/or analyzed will be available from the corresponding
author on reasonable request.
Declarations





The authors declare that they have no competing interests.
Author details
1Department of Medicine, University of Alberta, Edmonton, AB, Canada.
2Division of Nephrology, University of Cape Town, Cape Town, South Africa.
3John W. Scott Health Sciences Library, University of Alberta, Edmonton,
Alberta, Canada. 4Faculty of Science, University of Alberta, Edmonton,
Alberta, Canada. 5Division of Nephrology, Department of Medicine, McMaster
University, Hamilton, ON, Canada. 6Department of Family and Community
Medicine, University of Toronto, Toronto, ON, Canada. 7Department of Family
Medicine, University of Alberta, Edmonton, AB, Canada. 8Division of
Nephrology, Department of Medicine, McMaster University, Hamilton,
Ontario, Canada. 9Department of Health Research Methods, Evidence, and
Impact, McMaster University, Hamilton, Ontario, Canada. 10Department of
Non-Communicable Disease Epidemiology, London School of Hygiene and
Tropical Medicine, London, UK. 11Department of Community Health Sciences,
University of Calgary, Calgary, AB, Canada. 12Department of Family Medicine,
University of Calgary, Calgary, AB, Canada. 13Department of Medicine, Max
Rady College of Medicine, Winnipeg, MB, Canada. 14Division of Nephrology,
University of California, San Francisco, CA, USA. 15Kidney Health Research
Institute, University of California, San Francisco, CA, USA. 16Department of
Family Medicine, McMaster University, Hamilton, ON, Canada. 17Division of
Nephrology and Immunology, Faculty of Medicine and Dentistry, University
of Alberta, Edmonton, Alberta, Canada.
Received: 26 November 2020 Accepted: 23 June 2021
References
1. Donaldson LJ, Kelley ET, Dhingra-Kumar N, Kieny MP, Sheikh A. Medication
without harm: who's third global patient safety challenge. Lancet. 2017;
389(10080):1680–1. https://doi.org/10.1016/S0140-6736(17)31047-4.
2. Duerden M, Payne R, Avery T. Polypharmacy and medicines optimisation.
King's Fund Report, November 2013; 2013.
3. Mair A, Wilson M, Dreischulte T. Addressing the challenge of polypharmacy.
Annu Rev Pharmacol Toxicol. 2020;60(1):661–81. https://doi.org/10.1146/a
nnurev-pharmtox-010919-023508.
4. Jokanovic N, Tan EC, Dooley MJ, Kirkpatrick CM, Bell JS. Prevalence and
factors associated with polypharmacy in long-term care facilities: a
systematic review. J Am Med Dir Assoc. 2015;16(6):535 e531–12.
5. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in
prescription drug use among adults in the United States from 1999-2012.
JAMA. 2015;314(17):1818–30. https://doi.org/10.1001/jama.2015.13766.
6. Sarkar S. Geriatric poly-pharmacy: a growing epidemic. How to prevent it?
Br J Med Med Res. 2017;21:1–11.
7. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A
systematic review of definitions. BMC geriatrics. 2017;17(1):230. https://doi.
org/10.1186/s12877-017-0621-2.
8. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al.
Polypharmacy cutoff and outcomes: five or more medicines were used to
identify community-dwelling older men at risk of different adverse
outcomes. J Clin Epidemiol. 2012;65(9):989–95. https://doi.org/10.1016/j.
jclinepi.2012.02.018.
9. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology
of multimorbidity and implications for health care, research, and medical
education: a cross-sectional study. Lancet. 2012;380(9836):37–43. https://doi.
org/10.1016/S0140-6736(12)60240-2.
10. National Center for Health Statistics (US). Health, United States, 2016: With
Chartbook on Long-term Trends in Health. Hyattsville: National Center for
Health Statistics (US); 2017. Report No.: 2017-1232.
11. Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in
prescription and over-the-counter medication and dietary supplement use
among older adults in the United States, 2005 vs 2011. JAMA Intern Med.
2016;176(4):473–82. https://doi.org/10.1001/jamainternmed.2015.8581.
12. Proulx J, Hunt J. Drug use among seniors on public drug programs in
Canada, 2012. Healthcare Quarterly (Toronto). 2015;18(1):11–3.
13. Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical
consequences of polypharmacy in older adults: a narrative review. Expert
Opin Drug Saf. 2018;17(12):1185–96. https://doi.org/10.1080/14740338.2018.1
546841.
14. Davies LE, Spiers G, Kingston A, Todd A, Adamson J, Hanratty B. Adverse
outcomes of polypharmacy in older people: systematic review of reviews. J
Am Med Dir Assoc. 2020;21(2):181–7. https://doi.org/10.1016/j.jamda.2019.10.
022.
15. Khezrian M, McNeil CJ, Murray AD, Myint PK. An overview of prevalence,
determinants and health outcomes of polypharmacy. Ther Adv Drug Saf.
2020;11:2042098620933741.
16. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in
elderly. Expert Opin Drug Saf. 2014;13(1):57–65. https://doi.org/10.1517/1474
0338.2013.827660.
17. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice
guidelines and quality of care for older patients with multiple comorbid
diseases: implications for pay for performance. JAMA. 2005;294(6):716–24.
https://doi.org/10.1001/jama.294.6.716.
18. Mangin D, Bahat G, Golomb BA, Mallery LH, Moorhouse P, Onder G, et al.
International group for reducing inappropriate medication use &
polypharmacy (IGRIMUP): position statement and 10 recommendations for
action. Drugs Aging. 2018;35(7):575–87. https://doi.org/10.1007/s40266-018-
0554-2.
19. Garber J, Brownlee S. Medication overload: America's Other Drug Problem.
In. Brookline: The Lown Institute; 2019.
20. Garfinkel D, Ilhan B, Bahat G. Routine deprescribing of chronic medications
to combat polypharmacy. Ther Adv Drug Saf. 2015;6(6):212–33. https://doi.
org/10.1177/2042098615613984.
21. Moffat K, Mercer SW. Challenges of managing people with multimorbidity
in today’s healthcare systems. BMC Fam Pract. 2015;16(1):1–3.
22. Ahn R, Woodbridge A, Abraham A, Saba S, Korenstein D, Madden E,
Boscardin WJ, Keyhani S. Financial ties of principal investigators and
randomized controlled trial outcomes: cross sectional study. BMJ. 2017;356:
i6770. https://doi.org/10.1136/bmj.i6770.
23. Norris SL, Holmer HK, Ogden LA, Burda BU. Conflict of interest in clinical
practice guideline development: a systematic review. Plos One. 2011;6(10):
e25153. https://doi.org/10.1371/journal.pone.0025153.
24. Phillips KA, Veenstra D, Van Bebber S, Sakowski J. An introduction to cost-
effectiveness and cost-benefit analysis of pharmacogenomics.
Pharmacogenomics. 2003;4(3):231–9. https://doi.org/10.1517/phgs.4.3.231.22
691.
25. SA HLS: Under-reporting of adverse drug reactions: a systematic review.
Drug Saf 2006, 29(5):385-396, doi: https://doi.org/10.2165/00002018-20062
9050-00003.
Okpechi et al. Systematic Reviews          (2021) 10:198 Page 6 of 7
26. Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the
outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug
Saf. 2010;19(9):901–10. https://doi.org/10.1002/pds.1984.
27. Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association
between polypharmacy and death: A systematic review and meta-analysis. J
Am Pharm Assoc (2003). 2017;57(6):729–738.e710.
28. Tonelli M, Riella M. Chronic kidney disease and the aging population.
Brazilian J Nephrol. 2014;36(1):1–5. https://doi.org/10.5935/0101-2800.2014
0001.
29. Nitta K, Okada K, Yanai M, Takahashi S. Aging and chronic kidney disease.
Kidney Blood Pressure Res. 2013;38(1):109–20. https://doi.org/10.1159/0003
55760.
30. Titze S, Schmid M, Köttgen A, Busch M, Floege J, Wanner C, et al. Disease
burden and risk profile in referred patients with moderate chronic kidney
disease: composition of the German Chronic Kidney Disease (GCKD) cohort.
Nephrol Dial Transplan. 2015;30(3):441–51. https://doi.org/10.1093/ndt/gfu2
94.
31. USRDS. United States Renal Data System. 2018 USRDS annual data report:
Epidemiology of kidney disease in the United States. Bethesda: National
Institutes of Health, National Institute of Diabetes and Digestive and Kidney
Diseases; 2018.
32. Mason NA. Polypharmacy and medication-related complications in the
chronic kidney disease patient. Curr Opin Nephrol Hypertens. 2011;20(5):
492–7. https://doi.org/10.1097/MNH.0b013e328349c261.
33. Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM. Clinical
Pharmacokinetics in Kidney Disease: Fundamental Principles. Clin J Am Soc
Nephrol. 2018;13(7):1085–95. https://doi.org/10.2215/CJN.00340118.
34. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in
patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65(8):757–73.
https://doi.org/10.1007/s00228-009-0678-8.
35. Schmidt IM, Hübner S, Nadal J, Titze S, Schmid M, Bärthlein B, et al. Patterns
of medication use and the burden of polypharmacy in patients with
chronic kidney disease: the German Chronic Kidney Disease study. Clin
Kidney J. 2019;12(5):663–72. https://doi.org/10.1093/ckj/sfz046.
36. Secora A, Alexander GC, Ballew SH, Coresh J, Grams ME. Kidney function,
polypharmacy, and potentially inappropriate medication use in a
community-based cohort of older adults. Drugs Aging. 2018;35(8):735–50.
https://doi.org/10.1007/s40266-018-0563-1.
37. Morin L, Laroche M-L, Texier G, Johnell K. Prevalence of Potentially
Inappropriate Medication Use in Older Adults Living in Nursing Homes: A
Systematic Review. J Am Med Direct Assoc. 2016;17(9):862.e861–9.
38. Papaioannou A, Clarke JA, Campbell G, Bédard M. Assessment of adherence
to renal dosing guidelines in long-term care facilities. J Am Geriatr Soc.
2000;48(11):1470–3. https://doi.org/10.1111/j.1532-5415.2000.tb02639.x.
39. Chang F, O'Hare AM, Miao Y, Steinman MA. Use of Renally Inappropriate
Medications in Older Veterans: A National Study. J Am Geriatr Soc. 2015;
63(11):2290–7. https://doi.org/10.1111/jgs.13790.
40. Blix HS, Viktil KK, Moger TA, Reikvam A. Use of renal risk drugs in
hospitalized patients with impaired renal function--an underestimated
problem? Nephrol Dial Transplant. 2006;21(11):3164–71. https://doi.org/10.1
093/ndt/gfl399.
41. Laville SM, Metzger M, Stengel B, Jacquelinet C, Combe C, Fouque D, et al.
Evaluation of the adequacy of drug prescriptions in patients with chronic
kidney disease: results from the CKD-REIN cohort. Br J Clin Pharmacol. 2018;
84(12):2811–23. https://doi.org/10.1111/bcp.13738.
42. United Nations. World Population Prospects (The 2008 Revision).https://
www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/
files/files/documents/2020/Jan/un_2008_world_population_prospects-2008_
revision_volume-ii.pdf. Accessed 2 July 2021.
43. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al.
Preferred reporting items for systematic review and meta-analysis protocols
(PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. https://doi.org/10.1186/204
6-4053-4-1.
44. Page MJ, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C, et al.
Updating guidance for reporting systematic reviews: development of the
PRISMA 2020 statement; 2020.
45. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al.
Meta-analysis of observational studies in epidemiology: a proposal for
reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE)
group. JAMA. 2000;283(15):2008–12. https://doi.org/10.1001/jama.283.15.2
008.
46. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of
bias in prevalence studies: modification of an existing tool and evidence of
interrater agreement. J Clin Epidemiol. 2012;65(9):934–9. https://doi.org/10.1
016/j.jclinepi.2011.11.014.
47. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S,
et al. Synthesis without meta-analysis (SWiM) in systematic reviews:
reporting guideline. BMJ. 2020;368:l6890.
48. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in
meta-analyses. BMJ. 2003;327(7414):557–60. https://doi.org/10.1136/bmj.327.
7414.557.
49. Thompson SG, Higgins JP. How should meta-regression analyses be
undertaken and interpreted? Stat Med. 2002;21(11):1559–73. https://doi.
org/10.1002/sim.1187.
50. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis.
Stat Med. 2002;21(11):1539–58. https://doi.org/10.1002/sim.1186.
51. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. https://
doi.org/10.1136/bmj.315.7109.629.
52. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.
GRADE: an emerging consensus on rating quality of evidence and strength
of recommendations. BMJ. 2008;336(7650):924–6. https://doi.org/10.1136/
bmj.39489.470347.AD.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Okpechi et al. Systematic Reviews          (2021) 10:198 Page 7 of 7
